{"gene":"CST3","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1984,"finding":"Cystatin C (gamma-trace) was identified as a potent inhibitor of cysteine proteinases including papain, ficin, and human cathepsins B, H, and L, with the tightest binding to cathepsin B among known protein inhibitors. Its widespread distribution in tissues and extracellular fluids suggested a physiological role in regulating cysteine proteinase activity.","method":"Enzyme kinetic inhibition assays (Ki measurements) with purified protein from biological fluids","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay with purified protein, replicated across multiple proteinases and independently confirmed","pmids":["6203523"],"is_preprint":false},{"year":1986,"finding":"Six cysteine proteinase inhibitors were isolated from human urine by affinity chromatography; cystatin C had the highest molar concentration in seminal plasma, cerebrospinal fluid, and milk, and accounted for nearly all cysteine proteinase inhibitory activity in those biological fluids.","method":"Affinity chromatography on insolubilized carboxymethylpapain, ion-exchange chromatography, immunosorption, enzyme kinetic assays, immunochemical quantification","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution-level biochemical isolation with enzyme kinetic and immunochemical validation","pmids":["3488317"],"is_preprint":false},{"year":1986,"finding":"Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis (Icelandic type) were identified as a variant of cystatin C (gamma-trace) carrying an amino acid substitution (Gln for Leu at position 68), establishing that mutant cystatin C forms pathological amyloid deposits in brain arteries.","method":"Protein sequence analysis of amyloid fibril components isolated from patient brain tissue","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct protein sequence determination from isolated amyloid material","pmids":["3517880"],"is_preprint":false},{"year":1988,"finding":"A point mutation in the CST3 gene (abolishing an AluI restriction site) at the codon for leucine at position 68 was identified as the cause of hereditary cystatin C amyloid angiopathy (HCCAA), an autosomal dominant disorder causing brain hemorrhage and death.","method":"Southern blot analysis with cystatin C cDNA probe, restriction fragment length polymorphism (RFLP) analysis across eight affected families","journal":"Lancet","confidence":"High","confidence_rationale":"Tier 2 — molecular genetic causation established across multiple families with restriction site analysis","pmids":["2900981"],"is_preprint":false},{"year":1990,"finding":"The human CST3 gene has three exons, no TATA or CAAT boxes in the promoter, and shares features with housekeeping gene promoters (Sp1 sites, GC-rich region); it is ubiquitously expressed in all human tissues examined, with highest expression in seminal vesicles.","method":"Genomic cloning and sequencing of a 7.3 kb segment, Northern blot analysis across multiple tissues","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — complete gene structure determination with expression mapping across tissues","pmids":["2363674"],"is_preprint":false},{"year":1991,"finding":"Leucocyte elastase cleaves the Val-10–Gly-11 bond of cystatin C, removing the N-terminal decapeptide and reducing inhibitory affinity for papain by >240-fold, for cathepsins B and L by ~1000-fold, but for cathepsin H by only 5-fold. This established that the N-terminal segment is essential for inhibition of cathepsins B and L but not cathepsin H, and that leucocyte elastase can regulate extracellular cysteine-proteinase inhibitory activity.","method":"Proteolytic cleavage with leucocyte elastase, enzyme kinetic inhibition assays with papain and cathepsins B, H, L; peptidyl diazomethane inhibitor studies","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis-equivalent truncation and kinetic validation across multiple proteinases","pmids":["1996959"],"is_preprint":false},{"year":1993,"finding":"The CST3 gene and other family II cystatin genes are clustered on chromosome 20p11.2 within a 300-kb BssHII fragment, as established by FISH, Southern blot, and pulsed-field gel electrophoresis.","method":"FISH, Southern blot, pulsed-field gel electrophoresis (PFGE)","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 — three orthogonal mapping methods converging on same locus","pmids":["8486384"],"is_preprint":false},{"year":1993,"finding":"A G/A transition polymorphism in the CST3 coding region results in an Ala/Thr variation at the penultimate amino acid of the signal peptide, detectable by SstII restriction site loss (B allele), establishing this as the basis of the CST3 A/B polymorphism.","method":"Direct DNA sequencing, PCR-RFLP","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 1 — direct sequencing with functional variant identification","pmids":["8103758"],"is_preprint":false},{"year":1995,"finding":"The mouse Cst3 gene has the same overall organization as human CST3 with two introns at identical positions, a promoter lacking TATA/CAAT boxes but containing Sp1-binding motifs, an androgen-responsive element core sequence, and AP-1 binding sites; it is expressed in all thirteen tissues examined. Mouse Cst3 maps to distal chromosome 2.","method":"Genomic DNA sequencing (6.1 kb), Northern blot across 13 tissues, chromosomal mapping","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1 — complete gene structure determination with expression mapping","pmids":["7835704"],"is_preprint":false},{"year":1999,"finding":"Cystatin C is severely reduced in atherosclerotic and aneurysmal aortic lesions compared to normal vascular smooth muscle cells. In vitro, cytokine-stimulated vascular SMCs secrete cathepsins whose elastolytic activity is blocked when cystatin C secretion is induced by TGF-β1 treatment, establishing an imbalance between cysteine proteases and cystatin C as a mechanism in arterial wall remodeling.","method":"Immunohistochemistry of human lesions, in vitro elastolytic activity assays with TGF-β1-treated vascular SMCs, ultrasonographic measurement of aortic diameter correlated with serum cystatin C","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — in vitro functional assay linking TGF-β1-induced cystatin C secretion to cathepsin inhibition, replicated in human tissue analysis","pmids":["10545518"],"is_preprint":false},{"year":2001,"finding":"Crystal structure of human cystatin C revealed that the protein dimerizes through three-dimensional domain swapping, forming tight two-fold symmetric dimers while retaining secondary structure. The L68Q mutation (causing HCCAA) destabilizes the monomer and makes the partially unfolded intermediate less unstable, explaining increased aggregation propensity. Higher-order aggregates can arise through open-ended domain swapping.","method":"X-ray crystallography","journal":"Nature structural biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure determination with mechanistic interpretation of disease mutation","pmids":["11276250"],"is_preprint":false},{"year":2010,"finding":"The CST3 BB genotype leads to reduced secretion of cystatin C protein (in vitro) and was associated with lower CSF cystatin C levels and dementia in Lewy body disease patients. Demented patients had decreased CSF cystatin C, and the correlation between CSF cystatin C and Aβ42 levels was high in non-demented but poor in demented subjects, suggesting cystatin C acts as a carrier of soluble Aβ42 in CSF.","method":"CST3 genotyping, CSF immunoassay for cystatin C and Aβ42, correlation analysis in 132 subjects","journal":"Journal of Alzheimer's disease : JAD","confidence":"Medium","confidence_rationale":"Tier 3 — clinical sample analysis with functional inference from genotype-protein correlation; in vitro secretion data cited but not shown in this paper","pmids":["20157249"],"is_preprint":false},{"year":2018,"finding":"CST3 (cystatin C) exerts anti-fibrotic activity in kidney fibroblasts by blocking the TGF-β receptor signaling pathway, inducing apoptotic cell death and reducing collagen production in primary fibroblasts isolated from kidneys subjected to ureteral obstruction.","method":"Cytokine array screening, primary fibroblast cell assays (apoptosis, collagen production), TGF-β receptor signaling pathway analysis, in vivo mouse unilateral ureter obstruction model","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — cell-based functional assay with pathway analysis and in vivo validation, single lab","pmids":["29653105"],"is_preprint":false},{"year":2018,"finding":"CST3 (cystatin C) secreted by epithelial cells inhibits the growth and activation of lung fibroblasts by inactivating the TGF-Smad pathway. CST3 expression is markedly reduced in fibrotic mouse and human lungs, and restoration of CST3 alleviated fibrotic changes in mouse lungs.","method":"Conditioned media experiments, fibroblast proliferation/activation assays, TGF-Smad pathway analysis, in vivo mouse pulmonary fibrosis model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (conditioned media, pathway analysis, in vivo), single lab, consistent with kidney fibrosis paper","pmids":["29724997"],"is_preprint":false},{"year":2023,"finding":"TGF-β1 secreted by M2 macrophages downregulates CST3 expression in colorectal cancer cells to promote migration. Conversely, CST3 overexpression in CRC cells suppressed TGF-β1 expression in M2 macrophages. These findings establish a bidirectional regulatory relationship between CST3 and TGF-β1 in the tumor microenvironment.","method":"Co-culture system (Transwell), TGF-β1 neutralization, CST3 overexpression, in vivo mouse CRC model with MC-LR/AOM/DSS treatment","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with in vivo validation, single lab","pmids":["37445705"],"is_preprint":false},{"year":2024,"finding":"NR3C1 (a transcription factor) binds to the CST3 promoter and represses its transcription in osteoclast and osteoblast precursor cells. USP10-mediated deubiquitination stabilizes NR3C1, increasing its suppression of CST3. Downregulation of CST3 reversed the bone-protective effects of NR3C1 knockdown, placing CST3 downstream of USP10/NR3C1 in bone homeostasis regulation.","method":"Chromatin immunoprecipitation (ChIP) of NR3C1 at CST3 promoter, overexpression/knockdown experiments, in vivo ovariectomy mouse model","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP demonstrating direct promoter binding with functional epistasis validation in vivo","pmids":["39236936"],"is_preprint":false},{"year":2024,"finding":"CST3 promotes retinal vascular integrity by upregulating tight junction and adherens junction proteins (claudin-5, VE-cadherin, ZO-1) in retinal endothelial cells via the Rap1 signaling pathway. Silencing CST3 induced retinal vascular leakage in vivo, while intravitreal CST3 injection reduced leakage in oxygen-induced retinopathy mice.","method":"siRNA knockdown, exogenous protein addition, in vivo intravitreal injection, OIR mouse model, Western blot for Rap1 pathway components and junction proteins","journal":"Experimental eye research","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function and gain-of-function with pathway validation and in vivo confirmation, single lab","pmids":["39147193"],"is_preprint":false},{"year":2024,"finding":"Dominant stop-gain or frameshift variants in CST3 cause adult-onset leukodystrophy without amyloid angiopathy. Structural comparison of the variants suggests that C-terminal truncations of cystatin C render the protein more prone to aggregation, causing white matter degeneration with astrocyte activation/loss and oligodendrocyte apoptosis, distinct from the L68Q-associated amyloid angiopathy.","method":"Whole-exome/genome sequencing in 16 patients from 8 families, histopathological analysis of 2 autopsy cases, protein structural comparison","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and histopathological characterization of novel disease mechanism; mechanistic interpretation is structural inference pending direct validation","pmids":["38489591"],"is_preprint":false},{"year":2025,"finding":"TIMP1 interacts with CST3 in human dermal fibroblasts to promote fibroblast differentiation toward a myofibroblast phenotype, upregulating α-SMA and CTGF and enhancing proliferation and migration, contributing to skin scar formation.","method":"scRNA-seq and bulk RNA-seq analysis, in vitro co-culture, protein interaction analysis, overexpression/knockdown of TIMP1 and CST3","journal":"International immunopharmacology","confidence":"Low","confidence_rationale":"Tier 3 — single lab, mechanistic follow-up of interaction is partial; CST3's specific contribution not fully dissected from TIMP1","pmids":["40925202"],"is_preprint":false}],"current_model":"Cystatin C (CST3) is a ubiquitously secreted cysteine proteinase inhibitor that potently inhibits cathepsins B, H, L, and S via its N-terminal segment and wedge loop, dimerizes through three-dimensional domain swapping (with the amyloidogenic L68Q mutation destabilizing the monomer to promote aggregation and cerebral amyloid angiopathy); it regulates extracellular proteolysis in diverse contexts including vascular remodeling (by counterbalancing cathepsin-mediated elastolysis under TGF-β1 control), pulmonary and renal fibrosis (by blocking TGF-Smad signaling in fibroblasts), retinal vascular integrity (via Rap1-dependent tight junction upregulation), and bone homeostasis (transcriptionally suppressed by the USP10-stabilized NR3C1 transcription factor)."},"narrative":{"teleology":[{"year":1984,"claim":"Establishing cystatin C as a broad-spectrum cysteine proteinase inhibitor resolved the identity of 'gamma-trace' protein and defined its biochemical function as the dominant extracellular regulator of cathepsins B, H, and L.","evidence":"Enzyme kinetic inhibition assays (Ki measurements) with purified protein from biological fluids","pmids":["6203523"],"confidence":"High","gaps":["No structural basis for inhibitory mechanism yet determined","Physiological targets in vivo not identified"]},{"year":1986,"claim":"Demonstrating that cystatin C accounts for nearly all cysteine proteinase inhibitory activity in CSF, seminal plasma, and milk established it as the principal extracellular cystatin, while identification of mutant L68Q cystatin C in cerebral amyloid fibrils linked the gene to hereditary cerebral hemorrhage with amyloidosis (Icelandic type).","evidence":"Affinity chromatography with immunochemical quantification across body fluids; protein sequence analysis of amyloid fibrils from patient brain tissue","pmids":["3488317","3517880"],"confidence":"High","gaps":["Mechanism by which the L68Q mutation promotes amyloid formation unknown","No gene-level confirmation of the mutation"]},{"year":1988,"claim":"Identifying the L68Q point mutation in the CST3 gene across eight HCCAA families established the molecular genetic basis of this autosomal dominant cerebral amyloid angiopathy.","evidence":"Southern blot with cystatin C cDNA probe and RFLP analysis across affected families","pmids":["2900981"],"confidence":"High","gaps":["Structural mechanism of mutation-induced aggregation not resolved","No animal model of disease"]},{"year":1990,"claim":"Characterization of the CST3 gene structure — three exons, housekeeping-type promoter with Sp1 sites but no TATA/CAAT boxes — explained the ubiquitous tissue expression pattern and provided the basis for studying transcriptional regulation.","evidence":"Genomic cloning and sequencing of 7.3 kb segment; Northern blot across multiple human tissues","pmids":["2363674"],"confidence":"High","gaps":["Transcription factor regulation of the promoter not identified","No regulatory variant analysis"]},{"year":1991,"claim":"Showing that leucocyte elastase cleaves the N-terminal decapeptide of cystatin C, reducing cathepsin B/L inhibition >1000-fold while sparing cathepsin H inhibition, revealed that extracellular proteolytic processing modulates cystatin C's inhibitory specificity in vivo.","evidence":"Proteolytic cleavage with leucocyte elastase followed by enzyme kinetic assays against papain, cathepsins B, H, and L","pmids":["1996959"],"confidence":"High","gaps":["In vivo relevance of N-terminal processing at inflammatory sites not demonstrated","No structural explanation for differential effect on cathepsin H"]},{"year":1999,"claim":"Demonstrating that cystatin C is depleted in atherosclerotic and aneurysmal aortic lesions, and that TGF-β1 restores cystatin C secretion to block cathepsin-mediated elastolysis, established a protease–inhibitor imbalance mechanism in vascular remodeling.","evidence":"Immunohistochemistry of human vascular lesions; in vitro elastolytic activity assays with TGF-β1-treated vascular smooth muscle cells","pmids":["10545518"],"confidence":"High","gaps":["Causal role not tested by genetic deletion in vascular disease models","Which cathepsin(s) are the principal targets in vivo unclear"]},{"year":2001,"claim":"The crystal structure of cystatin C revealed three-dimensional domain swapping as the dimerization mechanism and showed that the L68Q mutation destabilizes the monomer, providing a structural explanation for aggregation and amyloid formation in HCCAA.","evidence":"X-ray crystallography of human cystatin C","pmids":["11276250"],"confidence":"High","gaps":["Kinetic pathway from domain-swapped dimer to amyloid fibril not resolved","No structure of the L68Q mutant itself"]},{"year":2018,"claim":"Two independent studies demonstrated that cystatin C suppresses fibroblast activation and collagen production in kidney and lung by blocking TGF-β/Smad signaling, expanding its function beyond direct protease inhibition to an anti-fibrotic signaling role.","evidence":"Primary fibroblast assays with pathway analysis and in vivo mouse models (unilateral ureter obstruction, pulmonary fibrosis)","pmids":["29653105","29724997"],"confidence":"Medium","gaps":["Molecular target on the TGF-β receptor complex not identified","Whether the anti-fibrotic activity requires protease-inhibitory function is untested"]},{"year":2024,"claim":"Discovery that cystatin C maintains retinal vascular barrier integrity through Rap1-dependent upregulation of tight junction proteins, and that dominant C-terminal truncating CST3 variants cause adult-onset leukodystrophy distinct from L68Q amyloid angiopathy, revealed new tissue-specific roles and a second disease mechanism.","evidence":"siRNA/recombinant protein experiments in retinal endothelial cells with OIR mouse model; whole-exome/genome sequencing in 16 leukodystrophy patients from 8 families with autopsy confirmation","pmids":["39147193","38489591"],"confidence":"Medium","gaps":["Rap1 activation mechanism by cystatin C unresolved","No biochemical characterization of truncated cystatin C aggregation properties","Leukodystrophy mechanism (astrocyte loss, oligodendrocyte apoptosis) not linked to protease inhibition or gain-of-function"]},{"year":2024,"claim":"Identification of NR3C1 as a direct transcriptional repressor of CST3, stabilized by USP10-mediated deubiquitination, established the first characterized transcription factor–promoter axis controlling cystatin C expression and linked it to bone homeostasis.","evidence":"ChIP of NR3C1 at the CST3 promoter; overexpression/knockdown with in vivo ovariectomy mouse model","pmids":["39236936"],"confidence":"Medium","gaps":["Whether NR3C1 regulation of CST3 operates in tissues beyond bone is unknown","Downstream bone-remodeling targets of cystatin C not identified"]},{"year":null,"claim":"Key unresolved questions include the molecular mechanism by which cystatin C inhibits TGF-β/Smad signaling independently of protease inhibition, the structural basis of C-terminal truncation-driven aggregation in leukodystrophy, and whether protease-inhibitory and signaling functions are separable in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["No separation-of-function mutant distinguishing protease inhibition from signaling roles","No structure of L68Q or C-terminal truncation variants","In vivo contribution of individual cathepsins to cystatin C-regulated processes not genetically dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,5,9]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,9,13]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,5]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,13,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,3,17]}],"complexes":[],"partners":["CTSB","CTSH","CTSL","TIMP1","NR3C1"],"other_free_text":[]},"mechanistic_narrative":"Cystatin C is a ubiquitously expressed, secreted cysteine proteinase inhibitor that potently inhibits cathepsins B, H, L, and other papain-family proteases, with its N-terminal segment essential for high-affinity inhibition of cathepsins B and L but dispensable for cathepsin H inhibition [PMID:6203523, PMID:1996959]. The protein dimerizes through three-dimensional domain swapping, and the amyloidogenic L68Q mutation destabilizes the monomer to promote aggregation underlying hereditary cystatin C amyloid angiopathy (HCCAA), while distinct C-terminal truncating variants cause adult-onset leukodystrophy without amyloid angiopathy [PMID:11276250, PMID:2900981, PMID:38489591]. Beyond protease inhibition, cystatin C exerts anti-fibrotic activity in lung and kidney by blocking TGF-β/Smad signaling in fibroblasts and maintains retinal vascular integrity by upregulating tight junction proteins via Rap1 signaling [PMID:29724997, PMID:29653105, PMID:39147193]. In vascular smooth muscle, TGF-β1 induces cystatin C secretion to counterbalance cathepsin-mediated elastolysis, and its depletion in atherosclerotic lesions contributes to arterial wall remodeling [PMID:10545518]."},"prefetch_data":{"uniprot":{"accession":"P01034","full_name":"Cystatin-C","aliases":["Cystatin-3","Gamma-trace","Neuroendocrine basic polypeptide","Post-gamma-globulin"],"length_aa":146,"mass_kda":15.8,"function":"As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P01034/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CST3","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CST3","total_profiled":1310},"omim":[{"mim_id":"621214","title":"LEUKODYSTROPHY, ADULT-ONSET, AUTOSOMAL DOMINANT, WITHOUT AMYLOID ANGIOPATHY; ADLDWA","url":"https://www.omim.org/entry/621214"},{"mim_id":"611953","title":"MACULAR DEGENERATION, AGE-RELATED, 11; ARMD11","url":"https://www.omim.org/entry/611953"},{"mim_id":"609731","title":"CYSTATIN 11; CST11","url":"https://www.omim.org/entry/609731"},{"mim_id":"608683","title":"CYSTATIN 8; CST8","url":"https://www.omim.org/entry/608683"},{"mim_id":"607116","title":"ALZHEIMER DISEASE 8","url":"https://www.omim.org/entry/607116"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Golgi apparatus","reliability":"Supported"},{"location":"Vesicles","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":4698.8},{"tissue":"choroid plexus","ntpm":3897.4}],"url":"https://www.proteinatlas.org/search/CST3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P01034","domains":[{"cath_id":"3.10.450.10","chopping":"39-144","consensus_level":"high","plddt":95.6821,"start":39,"end":144}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01034","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01034-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01034-F1-predicted_aligned_error_v6.png","plddt_mean":88.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CST3","jax_strain_url":"https://www.jax.org/strain/search?query=CST3"},"sequence":{"accession":"P01034","fasta_url":"https://rest.uniprot.org/uniprotkb/P01034.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01034/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01034"}},"corpus_meta":[{"pmid":"28423738","id":"PMC_28423738","title":"LncRNA Snhg1, a non-degradable sponge for miR-338, promotes expression of proto-oncogene CST3 in primary esophageal cancer cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28423738","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8486384","id":"PMC_8486384","title":"Cystatin C (CST3), the candidate gene for hereditary cystatin C amyloid angiopathy (HCCAA), and other members of the cystatin gene family are clustered on chromosome 20p11.2.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8486384","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2567273","id":"PMC_2567273","title":"The human cystatin C gene (CST3), mutated in hereditary cystatin C amyloid angiopathy, is located on chromosome 20.","date":"1989","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2567273","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11815350","id":"PMC_11815350","title":"CST3 genotype associated with exudative age related macular degeneration.","date":"2002","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/11815350","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2764935","id":"PMC_2764935","title":"The human cystatin C gene (CST3) is a member of the cystatin gene family which is localized on chromosome 20.","date":"1989","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2764935","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29653105","id":"PMC_29653105","title":"CST3 and GDF15 ameliorate renal fibrosis by inhibiting fibroblast growth and activation.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29653105","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7835704","id":"PMC_7835704","title":"Structural organization, expression and chromosomal mapping of the mouse cystatin-C-encoding gene (Cst3).","date":"1995","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/7835704","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29724997","id":"PMC_29724997","title":"Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29724997","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22435454","id":"PMC_22435454","title":"Meta-analysis of the cystatin C(CST3) gene G73A polymorphism and susceptibility to Alzheimer's disease.","date":"2012","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22435454","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20157249","id":"PMC_20157249","title":"The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease.","date":"2010","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/20157249","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25893795","id":"PMC_25893795","title":"A missense variant in CST3 exerts a recessive effect on susceptibility to age-related macular degeneration resembling its association with Alzheimer's disease.","date":"2015","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25893795","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8103758","id":"PMC_8103758","title":"An Ala/Thr variation in the coding region of the human cystatin C gene (CST3) detected as a SstII polymorphism.","date":"1993","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8103758","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20849835","id":"PMC_20849835","title":"Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3.","date":"2010","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/20849835","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18408364","id":"PMC_18408364","title":"Lack of an association between Alzheimer's disease and the cystatin C (CST3) gene G73A polymorphism in Mainland Chinese.","date":"2008","source":"Dementia and geriatric cognitive disorders","url":"https://pubmed.ncbi.nlm.nih.gov/18408364","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37445705","id":"PMC_37445705","title":"Microcystin-LR-Induced Interaction between M2 Tumor-Associated Macrophage and Colorectal Cancer Cell Promotes Colorectal Cancer Cell Migration through Regulating the Expression of TGF-β1 and CST3.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37445705","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19674067","id":"PMC_19674067","title":"The CST3 B haplotype is associated with frontotemporal lobar degeneration.","date":"2009","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19674067","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34721268","id":"PMC_34721268","title":"Association Between CST3 Gene Polymorphisms and Large-Artery Atherosclerotic Stroke.","date":"2021","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34721268","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35075612","id":"PMC_35075612","title":"Long Non-Coding RNA ZEB2-AS1 Augments Activity of Trophoblast Cells and Prevents the Development of Recurrent Spontaneous Abortion in Mice Through EZH2-Mediated CST3 Inhibition.","date":"2022","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/35075612","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33192475","id":"PMC_33192475","title":"Analyses Mutations in GSN, CST3, TTR, and ITM2B Genes in Chinese Patients With Alzheimer's Disease.","date":"2020","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33192475","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19293566","id":"PMC_19293566","title":"Flanking markers of cystatin c (CST3) gene do not show association with Alzheimer's disease.","date":"2009","source":"Dementia and geriatric cognitive disorders","url":"https://pubmed.ncbi.nlm.nih.gov/19293566","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38489591","id":"PMC_38489591","title":"Dominant CST3 variants cause adult onset leukodystrophy without amyloid angiopathy.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38489591","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32050196","id":"PMC_32050196","title":"Effects of CST3 Gene G73A Polymorphism on Cystatin C in a Prospective Multiethnic Cohort Study.","date":"2020","source":"Nephron","url":"https://pubmed.ncbi.nlm.nih.gov/32050196","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21577020","id":"PMC_21577020","title":"Association between CST3 rs2424577 polymorphism and corpulence related phenotypes during lifetime in populations of European ancestry.","date":"2011","source":"Obesity facts","url":"https://pubmed.ncbi.nlm.nih.gov/21577020","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39236936","id":"PMC_39236936","title":"USP10-mediated deubiquitination of NR3C1 regulates bone homeostasis by controlling CST3 expression.","date":"2024","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39236936","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39147193","id":"PMC_39147193","title":"CST3 alleviates retinal vascular leakage by regulating the Rap1 signaling pathway.","date":"2024","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/39147193","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34037438","id":"PMC_34037438","title":"Association of CST3 Gene with Its Protein: Cystatin C in Health and Severe Periodontal Disease.","date":"2021","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/34037438","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40925202","id":"PMC_40925202","title":"The ferroptosis-associated gene TIMP1 facilitates skin scar formation through the interaction with CST3 in fibroblasts.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40925202","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39914057","id":"PMC_39914057","title":"Cystatin C 3 (CST3) drives pathological progression in recurrent spontaneous abortion.","date":"2025","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39914057","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41033143","id":"PMC_41033143","title":"Two Japanese families with adult-onset leukoencephalopathy caused by pathogenic variants in CST3.","date":"2025","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41033143","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41167578","id":"PMC_41167578","title":"Multi-Omics discovery and clinical validation of IGFBP2, B2M, and CST3 as a serum biomarker panel for diabetic kidney disease progression.","date":"2025","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/41167578","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41534651","id":"PMC_41534651","title":"Non-neuronal cell microenvironment control retinal vascular remodeling by CST3 in the oxygen-induced retinopathy in mice.","date":"2026","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/41534651","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.07.16.665198","title":"Molecular Insights into Long COVID: Plasma Proteomics Reveals Oxidative Stress, Coagulation Cascade Activation, and Glycolytic Imbalance","date":"2025-07-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.16.665198","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.12.20.24319438","title":"Proteomic Profiling of Early-Stage Heart Failure Identifies Candidate Biomarkers and Molecular Pathways of Cardiac Inflammation in the Project Baseline Health Study","date":"2024-12-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.20.24319438","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.06.29.24309709","title":"A multi-phenotype approach implicates<i>SH2B3</i>in the genetics of chronic kidney disease","date":"2024-06-30","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.29.24309709","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17192785","id":"PMC_17192785","title":"Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17192785","citation_count":1399,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15086483","id":"PMC_15086483","title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement.","date":"2004","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/15086483","citation_count":807,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20383146","id":"PMC_20383146","title":"New loci associated with kidney function and chronic kidney disease.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20383146","citation_count":681,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19119287","id":"PMC_19119287","title":"Factors other than glomerular filtration rate affect serum cystatin C levels.","date":"2008","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/19119287","citation_count":628,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16713569","id":"PMC_16713569","title":"A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16713569","citation_count":610,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2363674","id":"PMC_2363674","title":"Structure and expression of the human cystatin C gene.","date":"1990","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/2363674","citation_count":523,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3488317","id":"PMC_3488317","title":"Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids.","date":"1986","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3488317","citation_count":434,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22622496","id":"PMC_22622496","title":"Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C.","date":"2012","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/22622496","citation_count":423,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10545518","id":"PMC_10545518","title":"Cystatin C deficiency in human atherosclerosis and aortic aneurysms.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10545518","citation_count":364,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11276250","id":"PMC_11276250","title":"Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping.","date":"2001","source":"Nature structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/11276250","citation_count":345,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6283552","id":"PMC_6283552","title":"Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis.","date":"1982","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6283552","citation_count":327,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3517880","id":"PMC_3517880","title":"Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace basic protein (cystatin C).","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3517880","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28904096","id":"PMC_28904096","title":"RIPK1 mediates a disease-associated microglial response in Alzheimer's disease.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28904096","citation_count":313,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6203523","id":"PMC_6203523","title":"The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors.","date":"1984","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/6203523","citation_count":282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15174051","id":"PMC_15174051","title":"An investigation into the human serum \"interactome\".","date":"2004","source":"Electrophoresis","url":"https://pubmed.ncbi.nlm.nih.gov/15174051","citation_count":247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19199708","id":"PMC_19199708","title":"Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).","date":"2009","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/19199708","citation_count":237,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15603510","id":"PMC_15603510","title":"Biochemistry and clinical role of human cystatin C.","date":"2004","source":"Critical reviews in clinical laboratory sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15603510","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20534741","id":"PMC_20534741","title":"Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20534741","citation_count":204,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23701892","id":"PMC_23701892","title":"Update on cystatin C: incorporation into clinical practice.","date":"2013","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/23701892","citation_count":203,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2900981","id":"PMC_2900981","title":"Mutation in cystatin C gene causes hereditary brain haemorrhage.","date":"1988","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/2900981","citation_count":175,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6365094","id":"PMC_6365094","title":"Human cystatin, a new protein inhibitor of cysteine proteinases.","date":"1984","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/6365094","citation_count":174,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16481598","id":"PMC_16481598","title":"Identification of potential CSF biomarkers in ALS.","date":"2006","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16481598","citation_count":173,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11780052","id":"PMC_11780052","title":"The DNA sequence and comparative analysis of human chromosome 20.","date":"2001","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11780052","citation_count":168,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1996959","id":"PMC_1996959","title":"Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase.","date":"1991","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/1996959","citation_count":167,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":17685,"output_tokens":3121,"usd":0.049935},"stage2":{"model":"claude-opus-4-6","input_tokens":6548,"output_tokens":2341,"usd":0.136898},"total_usd":0.425103,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":30287,"output_tokens":4462,"usd":0.078895},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":8210,"output_tokens":2608,"usd":0.159375}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"The human cystatin C gene (CST3) was assigned to chromosome 20 by Southern blot analysis of human-rodent somatic cell hybrids, establishing its chromosomal localization.\",\n      \"method\": \"Somatic cell hybrid analysis, Southern blot\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping, replicated by multiple independent studies\",\n      \"pmids\": [\"2567273\", \"2764935\", \"8486384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CST3 and other family II cystatin genes are clustered at chromosome 20p11.2, as determined by FISH, Southern blot, and pulsed-field gel electrophoresis mapping.\",\n      \"method\": \"FISH, Southern blot, PFGE\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal mapping methods in a single study\",\n      \"pmids\": [\"8486384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A G/A transition in the CST3 coding region results in an Ala/Thr variation at the penultimate amino acid of the signal peptide (p.Ala25Thr), detectable as a SstII restriction site polymorphism.\",\n      \"method\": \"Direct DNA sequencing, PCR-RFLP\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequencing with functional variant identification, replicated across studies\",\n      \"pmids\": [\"8103758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The mouse Cst3 gene has the same two-intron organization as the human CST3 gene; its promoter lacks TATA/CAAT boxes but contains Sp1-binding motifs, an androgen-responsive element core (TGTTCT), and AP-1 binding sites, suggesting transcriptional regulation by these factors.\",\n      \"method\": \"Genomic DNA sequencing, Northern blot, chromosomal mapping\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — sequence-based identification of regulatory elements without functional mutagenesis validation\",\n      \"pmids\": [\"7835704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The CST3 BB genotype (p.Ala25Thr homozygous) is associated with reduced cystatin C secretion in vitro and lower CSF cystatin C levels in vivo, indicating the variant affects protein secretion/production.\",\n      \"method\": \"Genotyping, CSF protein quantification, in vitro secretion assay (referenced)\",\n      \"journal\": \"Journal of Alzheimer's disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genotype-phenotype correlation with referenced in vitro secretion data\",\n      \"pmids\": [\"20157249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-338-3p directly targets CST3 mRNA to suppress cystatin C protein expression; lncRNA Snhg1 acts as a competing endogenous RNA sponge for miR-338-3p, thereby relieving miR-338-mediated repression of CST3 and promoting esophageal carcinoma cell growth.\",\n      \"method\": \"Luciferase reporter assay, RNA pull-down, gain/loss-of-function experiments, Western blot\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (luciferase, pulldown, functional rescue) in single lab\",\n      \"pmids\": [\"28423738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CST3 (cystatin C) exerts anti-fibrotic activity in kidney fibroblasts by blocking the TGF-β receptor signaling pathway, inducing apoptosis and reducing collagen production in primary fibroblasts.\",\n      \"method\": \"Cytokine array screening, primary fibroblast culture, apoptosis assay, collagen quantification, in vivo unilateral ureter obstruction model\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo functional assays with pathway identification, single lab\",\n      \"pmids\": [\"29653105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CST3 inhibits growth and activation of lung fibroblasts by inactivating the TGF-Smad signaling pathway; CST3 expression is reduced in fibrotic lungs and its restoration alleviates fibrotic changes in mice.\",\n      \"method\": \"Conditioned media experiments, fibroblast growth/activation assays, TGF-Smad pathway analysis, mouse pulmonary fibrosis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro pathway analysis plus in vivo rescue, single lab\",\n      \"pmids\": [\"29724997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"lncRNA ZEB2-AS1 recruits EZH2 to the CST3 promoter, increasing H3K27me3 modification to epigenetically suppress CST3 transcription, thereby enhancing trophoblast cell proliferation, migration, and invasion.\",\n      \"method\": \"ChIP assay, overexpression/silencing vectors, H3K27me3 methylation analysis, in vitro cell function assays, in vivo RSA mouse model\",\n      \"journal\": \"Reproductive sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct promoter binding with H3K27me3 readout plus functional rescue\",\n      \"pmids\": [\"35075612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TGF-β1 secreted by M2 macrophages downregulates CST3 expression in colorectal cancer cells; conversely, CST3 overexpression in CRC cells suppresses TGF-β1 expression in M2 macrophages, establishing a reciprocal regulatory loop that controls cancer cell migration.\",\n      \"method\": \"Transwell co-culture system, TGF-β1 neutralization, CST3 overexpression, in vivo CRC mouse model\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function in co-culture plus in vivo confirmation\",\n      \"pmids\": [\"37445705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The transcription factor NR3C1 binds the CST3 promoter to repress its transcription; USP10-mediated deubiquitination stabilizes NR3C1, thereby sustaining CST3 repression and affecting bone homeostasis through regulation of osteoclast and osteoblast differentiation.\",\n      \"method\": \"Chromatin immunoprecipitation (promoter binding), overexpression/knockdown in RAW264.7 and MC3T3-E1 cells, in vivo ovariectomy mouse model, ubiquitination assay\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding assay plus in vitro and in vivo functional validation\",\n      \"pmids\": [\"39236936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CST3 promotes retinal vascular integrity by activating the Rap1 signaling pathway, upregulating tight junction and adhesion molecules claudin-5, VE-cadherin, and ZO-1 in retinal endothelial cells; silencing CST3 induces retinal vascular leakage in vivo.\",\n      \"method\": \"siRNA silencing, exogenous protein addition, HRMEC migration/tubule formation assays, intravitreal injection in OIR mice, pathway analysis\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic pathway plus in vivo loss/gain-of-function, single lab\",\n      \"pmids\": [\"39147193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Dominant stop-gain or frameshift truncating variants in CST3 cause adult-onset leukodystrophy; structural comparison suggests these truncations render cystatin C more prone to aggregation, with associated astrocyte degeneration and oligodendrocyte apoptosis but without amyloid angiopathy.\",\n      \"method\": \"Human genetic sequencing, autopsy histopathology, structural protein modeling\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — human genetic and histopathological characterization across 8 families; protein aggregation mechanism is structural modeling only\",\n      \"pmids\": [\"38489591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TIMP1 interacts with CST3 in human dermal fibroblasts to promote fibroblast differentiation toward a myofibroblast phenotype, evidenced by upregulation of α-SMA and CTGF and enhanced proliferation and migration.\",\n      \"method\": \"scRNA-seq, bulk RNA-seq, co-immunoprecipitation/interaction assay, in vitro fibroblast differentiation assay\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — interaction identified from sequencing data with in vitro functional readout, single study\",\n      \"pmids\": [\"40925202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CST3 overexpression in trophoblast cells inhibits cloning and invasion, increases apoptosis and autophagy, and intensifies inflammatory and oxidative stress; silencing CST3 reverses these effects, demonstrating a direct inhibitory role of CST3 in trophoblast cell function.\",\n      \"method\": \"Overexpression/silencing vectors in trophoblast cells, proliferation, invasion, apoptosis, autophagy assays, oxidative stress measurement, RSA mouse model\",\n      \"journal\": \"Journal of reproductive immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with multiple orthogonal functional readouts\",\n      \"pmids\": [\"39914057\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CST3-encoded cystatin C is a secreted cysteine protease inhibitor whose transcription is regulated by NR3C1 (stabilized by USP10-mediated deubiquitination), miR-338-3p (sponged by lncRNA Snhg1), and EZH2-mediated H3K27me3 at its promoter (recruited by ZEB2-AS1); the protein activates Rap1 signaling to maintain retinal vascular tight junctions, inhibits TGF-β/Smad and TGF-β receptor pathways to suppress fibroblast activation, and its secretion is reduced by the signal-peptide variant p.Ala25Thr (CST3 B allele), while dominant C-terminal truncating variants cause aggregation-prone forms associated with adult-onset leukodystrophy.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1984,\n      \"finding\": \"Cystatin C (gamma-trace) was identified as a potent inhibitor of cysteine proteinases including papain, ficin, and human cathepsins B, H, and L, with the tightest binding to cathepsin B among known protein inhibitors. Its widespread distribution in tissues and extracellular fluids suggested a physiological role in regulating cysteine proteinase activity.\",\n      \"method\": \"Enzyme kinetic inhibition assays (Ki measurements) with purified protein from biological fluids\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with purified protein, replicated across multiple proteinases and independently confirmed\",\n      \"pmids\": [\"6203523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Six cysteine proteinase inhibitors were isolated from human urine by affinity chromatography; cystatin C had the highest molar concentration in seminal plasma, cerebrospinal fluid, and milk, and accounted for nearly all cysteine proteinase inhibitory activity in those biological fluids.\",\n      \"method\": \"Affinity chromatography on insolubilized carboxymethylpapain, ion-exchange chromatography, immunosorption, enzyme kinetic assays, immunochemical quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution-level biochemical isolation with enzyme kinetic and immunochemical validation\",\n      \"pmids\": [\"3488317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis (Icelandic type) were identified as a variant of cystatin C (gamma-trace) carrying an amino acid substitution (Gln for Leu at position 68), establishing that mutant cystatin C forms pathological amyloid deposits in brain arteries.\",\n      \"method\": \"Protein sequence analysis of amyloid fibril components isolated from patient brain tissue\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct protein sequence determination from isolated amyloid material\",\n      \"pmids\": [\"3517880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"A point mutation in the CST3 gene (abolishing an AluI restriction site) at the codon for leucine at position 68 was identified as the cause of hereditary cystatin C amyloid angiopathy (HCCAA), an autosomal dominant disorder causing brain hemorrhage and death.\",\n      \"method\": \"Southern blot analysis with cystatin C cDNA probe, restriction fragment length polymorphism (RFLP) analysis across eight affected families\",\n      \"journal\": \"Lancet\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — molecular genetic causation established across multiple families with restriction site analysis\",\n      \"pmids\": [\"2900981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The human CST3 gene has three exons, no TATA or CAAT boxes in the promoter, and shares features with housekeeping gene promoters (Sp1 sites, GC-rich region); it is ubiquitously expressed in all human tissues examined, with highest expression in seminal vesicles.\",\n      \"method\": \"Genomic cloning and sequencing of a 7.3 kb segment, Northern blot analysis across multiple tissues\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete gene structure determination with expression mapping across tissues\",\n      \"pmids\": [\"2363674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Leucocyte elastase cleaves the Val-10–Gly-11 bond of cystatin C, removing the N-terminal decapeptide and reducing inhibitory affinity for papain by >240-fold, for cathepsins B and L by ~1000-fold, but for cathepsin H by only 5-fold. This established that the N-terminal segment is essential for inhibition of cathepsins B and L but not cathepsin H, and that leucocyte elastase can regulate extracellular cysteine-proteinase inhibitory activity.\",\n      \"method\": \"Proteolytic cleavage with leucocyte elastase, enzyme kinetic inhibition assays with papain and cathepsins B, H, L; peptidyl diazomethane inhibitor studies\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis-equivalent truncation and kinetic validation across multiple proteinases\",\n      \"pmids\": [\"1996959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The CST3 gene and other family II cystatin genes are clustered on chromosome 20p11.2 within a 300-kb BssHII fragment, as established by FISH, Southern blot, and pulsed-field gel electrophoresis.\",\n      \"method\": \"FISH, Southern blot, pulsed-field gel electrophoresis (PFGE)\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — three orthogonal mapping methods converging on same locus\",\n      \"pmids\": [\"8486384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A G/A transition polymorphism in the CST3 coding region results in an Ala/Thr variation at the penultimate amino acid of the signal peptide, detectable by SstII restriction site loss (B allele), establishing this as the basis of the CST3 A/B polymorphism.\",\n      \"method\": \"Direct DNA sequencing, PCR-RFLP\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequencing with functional variant identification\",\n      \"pmids\": [\"8103758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The mouse Cst3 gene has the same overall organization as human CST3 with two introns at identical positions, a promoter lacking TATA/CAAT boxes but containing Sp1-binding motifs, an androgen-responsive element core sequence, and AP-1 binding sites; it is expressed in all thirteen tissues examined. Mouse Cst3 maps to distal chromosome 2.\",\n      \"method\": \"Genomic DNA sequencing (6.1 kb), Northern blot across 13 tissues, chromosomal mapping\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete gene structure determination with expression mapping\",\n      \"pmids\": [\"7835704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Cystatin C is severely reduced in atherosclerotic and aneurysmal aortic lesions compared to normal vascular smooth muscle cells. In vitro, cytokine-stimulated vascular SMCs secrete cathepsins whose elastolytic activity is blocked when cystatin C secretion is induced by TGF-β1 treatment, establishing an imbalance between cysteine proteases and cystatin C as a mechanism in arterial wall remodeling.\",\n      \"method\": \"Immunohistochemistry of human lesions, in vitro elastolytic activity assays with TGF-β1-treated vascular SMCs, ultrasonographic measurement of aortic diameter correlated with serum cystatin C\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro functional assay linking TGF-β1-induced cystatin C secretion to cathepsin inhibition, replicated in human tissue analysis\",\n      \"pmids\": [\"10545518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Crystal structure of human cystatin C revealed that the protein dimerizes through three-dimensional domain swapping, forming tight two-fold symmetric dimers while retaining secondary structure. The L68Q mutation (causing HCCAA) destabilizes the monomer and makes the partially unfolded intermediate less unstable, explaining increased aggregation propensity. Higher-order aggregates can arise through open-ended domain swapping.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Nature structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure determination with mechanistic interpretation of disease mutation\",\n      \"pmids\": [\"11276250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The CST3 BB genotype leads to reduced secretion of cystatin C protein (in vitro) and was associated with lower CSF cystatin C levels and dementia in Lewy body disease patients. Demented patients had decreased CSF cystatin C, and the correlation between CSF cystatin C and Aβ42 levels was high in non-demented but poor in demented subjects, suggesting cystatin C acts as a carrier of soluble Aβ42 in CSF.\",\n      \"method\": \"CST3 genotyping, CSF immunoassay for cystatin C and Aβ42, correlation analysis in 132 subjects\",\n      \"journal\": \"Journal of Alzheimer's disease : JAD\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — clinical sample analysis with functional inference from genotype-protein correlation; in vitro secretion data cited but not shown in this paper\",\n      \"pmids\": [\"20157249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CST3 (cystatin C) exerts anti-fibrotic activity in kidney fibroblasts by blocking the TGF-β receptor signaling pathway, inducing apoptotic cell death and reducing collagen production in primary fibroblasts isolated from kidneys subjected to ureteral obstruction.\",\n      \"method\": \"Cytokine array screening, primary fibroblast cell assays (apoptosis, collagen production), TGF-β receptor signaling pathway analysis, in vivo mouse unilateral ureter obstruction model\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-based functional assay with pathway analysis and in vivo validation, single lab\",\n      \"pmids\": [\"29653105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CST3 (cystatin C) secreted by epithelial cells inhibits the growth and activation of lung fibroblasts by inactivating the TGF-Smad pathway. CST3 expression is markedly reduced in fibrotic mouse and human lungs, and restoration of CST3 alleviated fibrotic changes in mouse lungs.\",\n      \"method\": \"Conditioned media experiments, fibroblast proliferation/activation assays, TGF-Smad pathway analysis, in vivo mouse pulmonary fibrosis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (conditioned media, pathway analysis, in vivo), single lab, consistent with kidney fibrosis paper\",\n      \"pmids\": [\"29724997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TGF-β1 secreted by M2 macrophages downregulates CST3 expression in colorectal cancer cells to promote migration. Conversely, CST3 overexpression in CRC cells suppressed TGF-β1 expression in M2 macrophages. These findings establish a bidirectional regulatory relationship between CST3 and TGF-β1 in the tumor microenvironment.\",\n      \"method\": \"Co-culture system (Transwell), TGF-β1 neutralization, CST3 overexpression, in vivo mouse CRC model with MC-LR/AOM/DSS treatment\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with in vivo validation, single lab\",\n      \"pmids\": [\"37445705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NR3C1 (a transcription factor) binds to the CST3 promoter and represses its transcription in osteoclast and osteoblast precursor cells. USP10-mediated deubiquitination stabilizes NR3C1, increasing its suppression of CST3. Downregulation of CST3 reversed the bone-protective effects of NR3C1 knockdown, placing CST3 downstream of USP10/NR3C1 in bone homeostasis regulation.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) of NR3C1 at CST3 promoter, overexpression/knockdown experiments, in vivo ovariectomy mouse model\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct promoter binding with functional epistasis validation in vivo\",\n      \"pmids\": [\"39236936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CST3 promotes retinal vascular integrity by upregulating tight junction and adherens junction proteins (claudin-5, VE-cadherin, ZO-1) in retinal endothelial cells via the Rap1 signaling pathway. Silencing CST3 induced retinal vascular leakage in vivo, while intravitreal CST3 injection reduced leakage in oxygen-induced retinopathy mice.\",\n      \"method\": \"siRNA knockdown, exogenous protein addition, in vivo intravitreal injection, OIR mouse model, Western blot for Rap1 pathway components and junction proteins\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function and gain-of-function with pathway validation and in vivo confirmation, single lab\",\n      \"pmids\": [\"39147193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Dominant stop-gain or frameshift variants in CST3 cause adult-onset leukodystrophy without amyloid angiopathy. Structural comparison of the variants suggests that C-terminal truncations of cystatin C render the protein more prone to aggregation, causing white matter degeneration with astrocyte activation/loss and oligodendrocyte apoptosis, distinct from the L68Q-associated amyloid angiopathy.\",\n      \"method\": \"Whole-exome/genome sequencing in 16 patients from 8 families, histopathological analysis of 2 autopsy cases, protein structural comparison\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and histopathological characterization of novel disease mechanism; mechanistic interpretation is structural inference pending direct validation\",\n      \"pmids\": [\"38489591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TIMP1 interacts with CST3 in human dermal fibroblasts to promote fibroblast differentiation toward a myofibroblast phenotype, upregulating α-SMA and CTGF and enhancing proliferation and migration, contributing to skin scar formation.\",\n      \"method\": \"scRNA-seq and bulk RNA-seq analysis, in vitro co-culture, protein interaction analysis, overexpression/knockdown of TIMP1 and CST3\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, mechanistic follow-up of interaction is partial; CST3's specific contribution not fully dissected from TIMP1\",\n      \"pmids\": [\"40925202\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Cystatin C (CST3) is a ubiquitously secreted cysteine proteinase inhibitor that potently inhibits cathepsins B, H, L, and S via its N-terminal segment and wedge loop, dimerizes through three-dimensional domain swapping (with the amyloidogenic L68Q mutation destabilizing the monomer to promote aggregation and cerebral amyloid angiopathy); it regulates extracellular proteolysis in diverse contexts including vascular remodeling (by counterbalancing cathepsin-mediated elastolysis under TGF-β1 control), pulmonary and renal fibrosis (by blocking TGF-Smad signaling in fibroblasts), retinal vascular integrity (via Rap1-dependent tight junction upregulation), and bone homeostasis (transcriptionally suppressed by the USP10-stabilized NR3C1 transcription factor).\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CST3 encodes cystatin C, a secreted cysteine protease inhibitor with broad roles in extracellular matrix homeostasis, fibrosis suppression, and vascular integrity. Cystatin C inhibits fibroblast activation and collagen production in kidney and lung by blocking TGF-β/Smad receptor signaling, and it maintains retinal vascular tight junctions by activating Rap1 signaling to upregulate claudin-5, VE-cadherin, and ZO-1 [PMID:29653105, PMID:29724997, PMID:39147193]. CST3 transcription is repressed by NR3C1 binding at its promoter (stabilized by USP10 deubiquitination) and by EZH2-mediated H3K27me3 deposition recruited by lncRNA ZEB2-AS1, while post-transcriptionally miR-338-3p suppresses CST3 mRNA, a repression relieved by the sponge lncRNA Snhg1 [PMID:39236936, PMID:35075612, PMID:28423738]. Dominant C-terminal truncating variants in CST3 cause aggregation-prone cystatin C and adult-onset leukodystrophy with astrocyte degeneration and oligodendrocyte apoptosis, while the signal-peptide variant p.Ala25Thr reduces cystatin C secretion [PMID:38489591, PMID:20157249].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Establishing the genomic identity of CST3 required mapping it to a specific chromosome; somatic cell hybrid analysis assigned it to chromosome 20, and subsequent FISH/PFGE refined the locus to 20p11.2 within a family II cystatin gene cluster.\",\n      \"evidence\": \"Southern blot of human-rodent somatic cell hybrids; FISH and PFGE mapping\",\n      \"pmids\": [\"2567273\", \"8486384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulatory elements within the cluster were not functionally characterized\", \"No expression data provided at this stage\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identifying natural coding variants was essential for understanding functional diversity; direct sequencing revealed the p.Ala25Thr signal peptide polymorphism (CST3 B allele), later shown to reduce cystatin C secretion and lower CSF protein levels.\",\n      \"evidence\": \"Direct DNA sequencing/PCR-RFLP (1993); CSF protein quantification and genotype correlation (2010)\",\n      \"pmids\": [\"8103758\", \"20157249\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Precise mechanism by which the signal peptide variant impairs secretion is unresolved\", \"Functional consequences in non-CNS tissues not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Understanding post-transcriptional regulation of CST3 revealed that miR-338-3p directly targets CST3 mRNA and that lncRNA Snhg1 sponges this miRNA to relieve repression, linking CST3 silencing to esophageal carcinoma cell growth.\",\n      \"evidence\": \"Luciferase reporter, RNA pull-down, gain/loss-of-function in cancer cells\",\n      \"pmids\": [\"28423738\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether this ceRNA axis operates outside esophageal carcinoma is untested\", \"Direct protease-inhibitory function was not assessed in this cancer context\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Determining how cystatin C influences tissue fibrosis showed that CST3 suppresses fibroblast activation and collagen production in both kidney and lung by blocking TGF-β/Smad receptor signaling, with in vivo rescue in fibrosis models.\",\n      \"evidence\": \"Primary fibroblast assays, TGF-β/Smad pathway analysis, unilateral ureter obstruction and pulmonary fibrosis mouse models\",\n      \"pmids\": [\"29653105\", \"29724997\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether anti-fibrotic activity requires protease inhibition or operates through a distinct receptor-mediated mechanism is unresolved\", \"Binding partner on fibroblasts mediating TGF-β pathway interference not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Epigenetic silencing of CST3 was demonstrated when lncRNA ZEB2-AS1 was shown to recruit EZH2 to the CST3 promoter, depositing H3K27me3 marks and repressing transcription, thereby promoting trophoblast invasion.\",\n      \"evidence\": \"ChIP assay for EZH2 and H3K27me3 at CST3 promoter, overexpression/silencing in trophoblast cells, RSA mouse model\",\n      \"pmids\": [\"35075612\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether EZH2-mediated silencing of CST3 is tissue-specific beyond trophoblasts is unknown\", \"Contribution of other chromatin marks at the CST3 locus not examined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Transcriptional control of CST3 was extended when NR3C1 was found to bind the CST3 promoter as a repressor, with USP10-mediated deubiquitination stabilizing NR3C1 protein to sustain this repression and regulate osteoclast/osteoblast differentiation.\",\n      \"evidence\": \"ChIP for NR3C1 at CST3 promoter, ubiquitination assay, RAW264.7/MC3T3-E1 cells, ovariectomy mouse model\",\n      \"pmids\": [\"39236936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NR3C1-mediated repression and EZH2-mediated silencing operate independently or cooperatively is unknown\", \"Direct glucocorticoid responsiveness of CST3 not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A vascular function for cystatin C was established: CST3 activates Rap1 signaling in retinal endothelial cells to upregulate tight junction proteins (claudin-5, VE-cadherin, ZO-1), and its silencing causes retinal vascular leakage in oxygen-induced retinopathy mice.\",\n      \"evidence\": \"siRNA silencing and exogenous protein addition in HRMECs, intravitreal injection in OIR mouse model\",\n      \"pmids\": [\"39147193\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor or direct binding target through which cystatin C activates Rap1 is not identified\", \"Whether protease inhibitory activity is required for vascular effects is untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A new Mendelian disease mechanism was revealed: dominant C-terminal truncating variants in CST3 produce aggregation-prone cystatin C and cause adult-onset leukodystrophy with astrocyte degeneration, distinct from hereditary cystatin C amyloid angiopathy.\",\n      \"evidence\": \"Genetic sequencing of 8 families, autopsy histopathology, structural protein modeling\",\n      \"pmids\": [\"38489591\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Aggregation propensity is inferred from structural modeling, not experimentally demonstrated\", \"Whether the truncated protein retains any protease inhibitory activity is unknown\", \"Mechanism of astrocyte-specific vulnerability not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A central unresolved question is whether cystatin C's diverse non-canonical signaling activities (TGF-β pathway inhibition, Rap1 activation) are mediated through its protease-inhibitory function or through direct receptor engagement, and the identity of such a receptor remains unknown.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No cell-surface receptor for cystatin C signaling has been identified\", \"Structure-function studies separating protease inhibition from signaling have not been performed\", \"In vivo confirmation of aggregation-driven pathology for truncating variants is lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 7, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 6, 7, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 7, 9, 11]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"NR3C1\",\n      \"EZH2\",\n      \"TIMP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Cystatin C is a ubiquitously expressed, secreted cysteine proteinase inhibitor that potently inhibits cathepsins B, H, L, and other papain-family proteases, with its N-terminal segment essential for high-affinity inhibition of cathepsins B and L but dispensable for cathepsin H inhibition [PMID:6203523, PMID:1996959]. The protein dimerizes through three-dimensional domain swapping, and the amyloidogenic L68Q mutation destabilizes the monomer to promote aggregation underlying hereditary cystatin C amyloid angiopathy (HCCAA), while distinct C-terminal truncating variants cause adult-onset leukodystrophy without amyloid angiopathy [PMID:11276250, PMID:2900981, PMID:38489591]. Beyond protease inhibition, cystatin C exerts anti-fibrotic activity in lung and kidney by blocking TGF-β/Smad signaling in fibroblasts and maintains retinal vascular integrity by upregulating tight junction proteins via Rap1 signaling [PMID:29724997, PMID:29653105, PMID:39147193]. In vascular smooth muscle, TGF-β1 induces cystatin C secretion to counterbalance cathepsin-mediated elastolysis, and its depletion in atherosclerotic lesions contributes to arterial wall remodeling [PMID:10545518].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Establishing cystatin C as a broad-spectrum cysteine proteinase inhibitor resolved the identity of 'gamma-trace' protein and defined its biochemical function as the dominant extracellular regulator of cathepsins B, H, and L.\",\n      \"evidence\": \"Enzyme kinetic inhibition assays (Ki measurements) with purified protein from biological fluids\",\n      \"pmids\": [\"6203523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural basis for inhibitory mechanism yet determined\", \"Physiological targets in vivo not identified\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Demonstrating that cystatin C accounts for nearly all cysteine proteinase inhibitory activity in CSF, seminal plasma, and milk established it as the principal extracellular cystatin, while identification of mutant L68Q cystatin C in cerebral amyloid fibrils linked the gene to hereditary cerebral hemorrhage with amyloidosis (Icelandic type).\",\n      \"evidence\": \"Affinity chromatography with immunochemical quantification across body fluids; protein sequence analysis of amyloid fibrils from patient brain tissue\",\n      \"pmids\": [\"3488317\", \"3517880\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which the L68Q mutation promotes amyloid formation unknown\", \"No gene-level confirmation of the mutation\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Identifying the L68Q point mutation in the CST3 gene across eight HCCAA families established the molecular genetic basis of this autosomal dominant cerebral amyloid angiopathy.\",\n      \"evidence\": \"Southern blot with cystatin C cDNA probe and RFLP analysis across affected families\",\n      \"pmids\": [\"2900981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism of mutation-induced aggregation not resolved\", \"No animal model of disease\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Characterization of the CST3 gene structure — three exons, housekeeping-type promoter with Sp1 sites but no TATA/CAAT boxes — explained the ubiquitous tissue expression pattern and provided the basis for studying transcriptional regulation.\",\n      \"evidence\": \"Genomic cloning and sequencing of 7.3 kb segment; Northern blot across multiple human tissues\",\n      \"pmids\": [\"2363674\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factor regulation of the promoter not identified\", \"No regulatory variant analysis\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Showing that leucocyte elastase cleaves the N-terminal decapeptide of cystatin C, reducing cathepsin B/L inhibition >1000-fold while sparing cathepsin H inhibition, revealed that extracellular proteolytic processing modulates cystatin C's inhibitory specificity in vivo.\",\n      \"evidence\": \"Proteolytic cleavage with leucocyte elastase followed by enzyme kinetic assays against papain, cathepsins B, H, and L\",\n      \"pmids\": [\"1996959\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of N-terminal processing at inflammatory sites not demonstrated\", \"No structural explanation for differential effect on cathepsin H\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrating that cystatin C is depleted in atherosclerotic and aneurysmal aortic lesions, and that TGF-β1 restores cystatin C secretion to block cathepsin-mediated elastolysis, established a protease–inhibitor imbalance mechanism in vascular remodeling.\",\n      \"evidence\": \"Immunohistochemistry of human vascular lesions; in vitro elastolytic activity assays with TGF-β1-treated vascular smooth muscle cells\",\n      \"pmids\": [\"10545518\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal role not tested by genetic deletion in vascular disease models\", \"Which cathepsin(s) are the principal targets in vivo unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The crystal structure of cystatin C revealed three-dimensional domain swapping as the dimerization mechanism and showed that the L68Q mutation destabilizes the monomer, providing a structural explanation for aggregation and amyloid formation in HCCAA.\",\n      \"evidence\": \"X-ray crystallography of human cystatin C\",\n      \"pmids\": [\"11276250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetic pathway from domain-swapped dimer to amyloid fibril not resolved\", \"No structure of the L68Q mutant itself\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Two independent studies demonstrated that cystatin C suppresses fibroblast activation and collagen production in kidney and lung by blocking TGF-β/Smad signaling, expanding its function beyond direct protease inhibition to an anti-fibrotic signaling role.\",\n      \"evidence\": \"Primary fibroblast assays with pathway analysis and in vivo mouse models (unilateral ureter obstruction, pulmonary fibrosis)\",\n      \"pmids\": [\"29653105\", \"29724997\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular target on the TGF-β receptor complex not identified\", \"Whether the anti-fibrotic activity requires protease-inhibitory function is untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that cystatin C maintains retinal vascular barrier integrity through Rap1-dependent upregulation of tight junction proteins, and that dominant C-terminal truncating CST3 variants cause adult-onset leukodystrophy distinct from L68Q amyloid angiopathy, revealed new tissue-specific roles and a second disease mechanism.\",\n      \"evidence\": \"siRNA/recombinant protein experiments in retinal endothelial cells with OIR mouse model; whole-exome/genome sequencing in 16 leukodystrophy patients from 8 families with autopsy confirmation\",\n      \"pmids\": [\"39147193\", \"38489591\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Rap1 activation mechanism by cystatin C unresolved\", \"No biochemical characterization of truncated cystatin C aggregation properties\", \"Leukodystrophy mechanism (astrocyte loss, oligodendrocyte apoptosis) not linked to protease inhibition or gain-of-function\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of NR3C1 as a direct transcriptional repressor of CST3, stabilized by USP10-mediated deubiquitination, established the first characterized transcription factor–promoter axis controlling cystatin C expression and linked it to bone homeostasis.\",\n      \"evidence\": \"ChIP of NR3C1 at the CST3 promoter; overexpression/knockdown with in vivo ovariectomy mouse model\",\n      \"pmids\": [\"39236936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NR3C1 regulation of CST3 operates in tissues beyond bone is unknown\", \"Downstream bone-remodeling targets of cystatin C not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the molecular mechanism by which cystatin C inhibits TGF-β/Smad signaling independently of protease inhibition, the structural basis of C-terminal truncation-driven aggregation in leukodystrophy, and whether protease-inhibitory and signaling functions are separable in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No separation-of-function mutant distinguishing protease inhibition from signaling roles\", \"No structure of L68Q or C-terminal truncation variants\", \"In vivo contribution of individual cathepsins to cystatin C-regulated processes not genetically dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 5, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 9, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 13, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 3, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CTSB\", \"CTSH\", \"CTSL\", \"TIMP1\", \"NR3C1\"],\n    \"other_free_text\": []\n  }\n}\n```"}